RLM.L Regulatory News (RLM)

PuriCore plc ("PuriCore or the "Company")

Announces the appointment of Alex Martin as CEO

Life Sciences executive to drive future strategy

19 May 2015 - PuriCore plc (AIM: PURI), an international company focused on safe and effective protection against the spread of infectious pathogens, today announces that Alex Martin will be appointed to the Board as Chief Executive Officer (CEO) following the Company's Annual General Meeting on 18 June 2015. Alex will join the Company on 1 June to permit a smooth transition with the retiring CEO, Michael Ashton. Alex will be based at PuriCore's headquarters in Malvern, PA.

Alex, aged 47, has more than 25 years' experience having held senior positions in both private and public companies principally in the pharmaceutical and biopharmaceutical industry. Alex previously served as a Chief Executive Officer of Affectis Pharmaceuticals AG, Chief Operating Officer of Intercept Pharmaceuticals (NASD: ICPT), and Chief Business Officer at Bioxell S.p.A, which was acquired by Cosmo Pharmaceuticals S.A. He began his career at SmithKline Beecham Pharmaceuticals before joining Novartis as Vice President, Global Business Development & Licensing. Most recently, Alex served as President at moksha8, a leading Latin American specialty pharmaceutical company.

Alex holds a BA from Cornell University and an MBA from Harvard. He brings a wealth of strategic, commercial and operational experience. He has successfully developed and launched new products, driven operational improvements, negotiated sizeable licensing arrangements and led successful IPOs and private fundraising initiatives. Alex has worked in five countries (including many in Europe) and speaks several languages.

Charles Spicer, Non-Executive Chairman of PuriCore, commented:

"We are delighted to welcome Alex to PuriCore at an important time in the Company's development. We are confident that with his broad operational background and leadership experience across a range of companies, he is well suited to enable us to capitalize on the opportunities identified in our strategic and operational review as well as to identify potential new ones."

Alex Martin, CEO Designate, remarked:

"I'm very pleased to be joining PuriCore at this time, and look forward to building on the Company's successes and helping chart the next phase of the Company's growth."

John Alexander Martin was a director of Affectis Pharmaceuticals AG during the past five years. Save as disclosed in this announcement, there are no further disclosures required under Rule 17 or Schedule 2 (g) of the AIM Rules for Companies.

-Ends-

Enquiries:

About PuriCore

PuriCore is an international company focused on developing and commercialising safe and effective products to protect against the spread of infectious pathogens based on its proprietary hypochlorous acid platform technology. Its products are currently used in two broad market segments: Supermarket Retail and Health Sciences. PuriCore's products do not cause harm to human or animal life or to the environment.

In the Supermarket Retail segment, PuriCore offers products to US retailers for use in their fresh produce departments to improve food safety and quality, to extend shelf life and to decrease food wastage. Our product is an eco-friendly, food-safe sanitising solution at a neutral PH that is used to protect produce from cross contamination and improve freshness. Our Sterilox Fresh Systems® are capital equipment that are installed at customer locations and allow for generation of solution as needed at the store. ProduceFresh®is our concentrate bottled version providing the same levels of stability, freshness and quality in a convenient consumable package. Additionally, the Company's FloraFresh® products, also sold as a concentrate in bottled form, protect against fungal growth and extend the life of cut flowers, with an initial focus on supermarket floral departments.

In Health Sciences, PuriCore's Wound Care business provides products that are used to treat chronic and acute wounds, including diabetic ulcers and burns in humans. A range of products have also been developed to manage wounds in companion and farm animals. The Company's Dermatology business is currently focused on treatments for atopic dermatitis. PuriCore is headquartered in Malvern, Pennsylvania.

Certain statements made in this announcement are forward-looking statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements. The Company cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.